

# ARGENX SE

ISIN: NL0010832176 WKN: - Asset Class: **Stock**

## Company

2024/10/18 17:38:50



Price  
**509.40**  
EUR

Difference 1.31%(6.60)



## Contact Details

ARGENX SE Tel: +31-76-303-04-88  
-- Fax: +  
Laarderhoogtweg 25 Web: <http://www.argen-x.com>  
1101 EB Amsterdam E-mail: [info@argenx.com](mailto:info@argenx.com)

## Company Profile

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

## Financial figures, Fiscal year: from 01.01. to 31.12.

| Financial figures              | 2023          |                        | 2022          |                        | 2021          |                        |
|--------------------------------|---------------|------------------------|---------------|------------------------|---------------|------------------------|
|                                | Assets        | Liabilities and equity | Assets        | Liabilities and equity | Assets        | Liabilities and equity |
| Current assets                 | 3,733,071,000 |                        | 2,599,389,000 |                        | 2,236,168,000 |                        |
| Common stock capital           |               | 6,389,000              |               | 6,221,000              |               | 5,481,000              |
| Fixed assets                   | 379,053,000   |                        | 337,374,000   |                        | 270,227,000   |                        |
| Equity capital of a company    |               | 3,709,326,000          |               | 2,636,401,000          |               | 2,228,476,000          |
| Cash and cash equivalents      | 1,854,744,000 |                        | 793,536,000   |                        | 1,237,889,000 |                        |
| Accrued liabilities            |               | 1,311,000              |               | 815,000                |               | 366,000                |
| Other assets                   |               | -                      |               | -                      |               | -                      |
| Current liabilities            |               | 382,920,000            |               | 283,229,000            |               | 264,895,000            |
| Prepayments and accrued income |               | -                      |               | -                      |               | -                      |
| Non-current liabilities        |               | 19,877,000             |               | 17,132,000             |               | 13,024,000             |
| Different income               |               | -                      |               | -                      |               | -                      |
| Other liabilities              |               | 0                      |               | 0                      |               | 0                      |
| Total assets                   | 4,112,124,000 | 4,112,124,000          | 2,936,763,000 | 2,936,763,000          | 2,506,396,000 | 2,506,396,000          |

## Balance notes

|                     | 2023   | 2022   | 2021   |
|---------------------|--------|--------|--------|
| Accounting standard | IFRS   | IFRS   | IFRS   |
| Employees           | 1,148  | 843    | 650    |
| Equity ratio        | 90.20% | 89.77% | 88.91% |
| Debt-equity ratio   | 10.86% | 11.39% | 12.47% |

## Others

|                  | 2023   | 2022  | 2021  |
|------------------|--------|-------|-------|
| Tax Expense Rate | 11.36% | 5.24% | 1.32% |

## Income statement

|  | 2023          | 2022         | 2021         |
|--|---------------|--------------|--------------|
| <b>Turnover</b>  | 1,134,306,000 | 390,824,000  | 420,714,000  |
| <b>Net income</b>  | -272,915,000  | -675,177,000 | -345,407,000 |
| <b>EBIT</b>  | -388,448,746  | -733,307,168 | -352,042,061 |
| <b>Operating income before taxes</b>                                 | -303,297,000  | -711,852,000 | -350,016,000 |
| <b>Cash Flow</b>   | -302,996,000  | -808,450,000 | -511,183,000 |
| <b>Net interest income</b>   | 85,150,000    | 21,454,000   | 2,025,000    |
| <b>Research and development expenses</b>                             | 697,377,000   | 534,013,000  | 487,975,000  |
| <b>Income taxes</b>  | -34,462,000   | -37,319,000  | -4,609,000   |
| <b>Result from investments in subsidiaries, associates and other</b> | -4,080,000    | -644,000     | 0            |
| <b>Revenues per employee</b>   | 988,071       | 463,611      | 647,254      |

## Board of Directors

|                        |                               |
|------------------------|-------------------------------|
| Peter K. M. Verhaeghe  | Chairman of Supervisory Board |
| Ana Cespedes           | Member of Supervisory Board   |
| Brian Kotzin           | Member of Supervisory Board   |
| Joseph deBethizy       | Member of Supervisory Board   |
| Pamela Klein           | Member of Supervisory Board   |
| Anthony Adam Rosenberg | Member of Supervisory Board   |
| Camilla Sylvest        | Member of Supervisory Board   |
| James Daly             | Member of Supervisory Board   |
| Steve Kroghes          | Member of Supervisory Board   |

## Members of Management Board

|                      |                               |
|----------------------|-------------------------------|
| Tim Van Hauwermeiren | Chairman of Managing Board    |
| Andria Wilk          | Member of Executive Committee |
| Arjen Lemmen         | Member of Executive Committee |
| Beth DelGiaccio      | Member of Executive Committee |
| Filip Borgions       | Member of Executive Committee |
| Karen Massey         | Member of Executive Committee |
| Karl Gubitz          | Member of Executive Committee |
| Luc Truyen           | Member of Executive Committee |
| Malini Moorthy       | Member of Executive Committee |
| Marc Schorpion       | Member of Executive Committee |
| Peter Ulrichs        | Member of Executive Committee |